|
Gender
|
|
Women, n (%)
|
305 (38.22)
|
825 (30.89)
|
15.04
|
< 0.01
|
|
Men, n (%)
|
493 (61.78)
|
1846 (69.11)
|
|
Age, year
|
71.64 ± 9.96
|
67.30 ± 12.01
|
−10.28
|
< 0.01
|
|
Body mass index, kg/m2
|
25.20 ± 3.26
|
24.75 ± 3.35
|
−3.35
|
< 0.01
|
|
Hypertension, n (%)
|
352 (44.11)
|
907 (33.96)
|
27.39
|
< 0.01
|
|
Diabetes mellitus,n (%)
|
171 (21.43)
|
531 (19.88)
|
0.91
|
0.34
|
|
Heart failure, n (%)
|
424 (53.13)
|
1510 (56.53)
|
2.88
|
0.09
|
|
Vascular disease, n (%)
|
121 (15.16)
|
263 (9.85)
|
17.64
|
< 0.01
|
|
CHA2DS2-VASc score, mean
|
4.96 ± 1.37
|
2.47 ± 1.40
|
−44.45
|
< 0.01
|
|
Smoking, n (%)
|
269 (33.71)
|
660 (24.71)
|
25.38
|
< 0.01
|
|
Drinking, n (%)
|
124 (15.54)
|
371 (13.89)
|
1.37
|
0.24
|
|
TG, mmol/L
|
1.11 ± 0.67
|
1.14 ± 0.89
|
1.08
|
0.28
|
|
TC, mmol/L
|
3.57 ± 1.29
|
3.48 ± 1.47
|
−1.55
|
0.12
|
|
non-HDL-C, mmol/L
|
2.65 ± 1.25
|
2.48 ± 1.42
|
−3.10
|
< 0.01
|
|
LDL-C, mmol/L
|
2.58 ± 1.02
|
1.69 ± 0.86
|
−22.18
|
< 0.01
|
|
HDL-C, mmol/L
|
0.92 ± 0.39
|
1.00 ± 0.34
|
5.47
|
< 0.01
|
|
LDL-C/HDL-C
|
2.83 (1.83, 4.09)
|
1.55 (1.10, 2.27)
|
−22.17
|
< 0.01
|
|
Uric acid, umol/L
|
278.54 ± 147.06
|
295.71 ± 145.64
|
2.92
|
< 0.01
|
|
Creatinine, mmol/L
|
75.44 ± 37.23
|
76.00 ± 59.92
|
0.32
|
0.75
|
|
Blood urea nitrogen, mmol/L
|
5.97 ± 2.68
|
6.05 ± 2.77
|
0.67
|
0.50
|
|
Fasting plasma glucose, mmol/L
|
5.93 ± 2.44
|
5.75 ± 2.29
|
−1.92
|
0.06
|
|
Previous Medications
|
|
Anti-hypertensive drugs, n (%)
|
287 (35.96)
|
754 (28.23)
|
17.51
|
< 0.01
|
|
Anti-diabetic agents, n (%)
|
141 (17.67)
|
420 (15.72)
|
1.71
|
0.19
|
|
Statins, n (%)
|
85 (10.65)
|
345 (12.92)
|
2.90
|
0.09
|
|
anti-platelet drugs, n (%)
|
150 (18.80)
|
583 (21.83)
|
3.39
|
0.07
|
|
anticoagulant drugs, n (%)
|
189 (23.68)
|
656 (24.56)
|
0.26
|
0.61
|
